Non-small cell lung cancer, version 3.2022: NCCN Clinical Practice Guidelines in Oncology Guidelines
| Authors: | Ettinger, D. S.; Wood, D. E.; Aisner, D. L.; Akerley, W.; Bauman, J. R.; Bharat, A.; Bruno, D. S.; Chang, J. Y.; Chirieac, L. R.; D'Amico, T. A.; DeCamp, M.; Dilling, T. J.; Dowell, J.; Gettinger, S.; Grotz, T. E.; Gubens, M. A.; Hegde, A.; Lackner, R. P.; Lanuti, M.; Lin, J.; Loo, B. W. Jr; Lovly, C. M.; Maldonado, F.; Massarelli, E.; Morgensztern, D.; Ng, T.; Otterson, G. A.; Pacheco, J. M.; Patel, S. P.; Riely, G. J.; Riess, J.; Schild, S. E.; Shapiro, T. A.; Singh, A. P.; Stevenson, J.; Tam, A.; Tanvetyanon, T.; Yanagawa, J.; Yang, S. C.; Yau, E.; Gregory, K.; Hughes, M. |
| Title: | Non-small cell lung cancer, version 3.2022: NCCN Clinical Practice Guidelines in Oncology |
| Abstract: | NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations. |
| Keywords: | genetics; neoplasm recurrence, local; carcinoma, non-small-cell lung; lung neoplasms; oncology; lung tumor; immunotherapy; tumor recurrence; medical oncology; non small cell lung cancer; humans; human |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 20 |
| Issue: | 5 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2022-05-01 |
| Start Page: | 497 |
| End Page: | 530 |
| Language: | English |
| DOI: | 10.6004/jnccn.2022.0025 |
| PUBMED: | 35545176 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2022 -- Source: Scopus |
